Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study

Cancer

Volumn 119, Issue 19, 2013, Pages 3429-3435

  Leone, Francesco ^a   Artale, Salvatore ^b   Marino, Donatella ^a   Cagnazzo, Celeste ^a   Cascinu, Stefano ^c   Pinto, Carmine ^d   Fornarini, Giuseppe ^e   Tampellini, Marco ^f   Di Fabio, Francesca ^d   Sartore Bianchi, Andrea ^b   De Carlis, Luciano ^b   Pugliese, Raffaele ^b   Capussotti, Lorenzo ^g   Gioeni, Luisa ^a   Siena, Salvatore ^b   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c Azienda Ospedaliera Umberto I   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f SAN LUIGI GONZAGA HOSPITAL   (Italy)

^g MAURIZIANO HOSPITAL   (Italy)

Author keywords

capecitabine plus oxaliplatin (XELOX) chemotherapy; colon cancer; liver metastasis; liver resection; panitumumab

Indexed keywords

CAPECITABINE; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; LIVER SURGERY; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

CAPECITABINE PLUS OXALIPLATIN (XELOX) CHEMOTHERAPY; COLON CANCER; LIVER METASTASIS; LIVER RESECTION; PANITUMUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84884910001     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28223     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
3. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 1407-1412.
4. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR,. Phase III comparison of 2 irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003; 21: 807-814.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
7. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999; 35: 1343-1347.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318; discussion 318-321.
9. Vigano L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L,. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol. 2012; 19: 2035-2044.
10. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240: 644-657; discussion 657-658.
11. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25: 1670-1676.
12. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011; 22: 2042-2048.
13. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH,. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005; 16: 1311-1319.
14. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25: 4593-4602.
15. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007; 25: 5225-5232.
16. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004; 58: 984-990.
17. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
18. A'Hern RP,. Sample size tables for exact single-stage phase II designs. Statist Med 2001; 20: 859-866.
19. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11: 38-47.
20. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010; 103: 1542-1547.
21. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
22. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-4705.
23. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 4706-4713.
24. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-1664.
25. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol. 2010; 28 (suppl):Page. Abstract 3570.
26. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.